Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers

INTRODUCTION: Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restric...

Descripción completa

Detalles Bibliográficos
Autores principales: Tikkanen, Antti, Iivanainen, Sanna, Koivunen, Jussi P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324422/
https://www.ncbi.nlm.nih.gov/pubmed/32306129
http://dx.doi.org/10.1007/s00432-020-03217-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324422/
https://www.ncbi.nlm.nih.gov/pubmed/32306129
http://dx.doi.org/10.1007/s00432-020-03217-7

Ejemplares similares